Timeline, a pioneering biotech firm at the front of longevity research, has achieved a significant milestone in its mission to develop interventions that could help people maintain their health for longer. The company recently unveiled the promising results of a landmark clinical trial investigating the effects of its proprietary compound, Mitopure, on immune aging. We have been taking Mitopure for two years now and, beyond how great it makes us feel, we appreciate Timeline’s commitment to vigorous testing.
The MitoImmune Study
The study, dubbed MitoImmune, was a collaborative effort between Timeline and two prestigious research institutions: the Georg-Speyer-Haus Institute for Tumor and Experimental Therapy in Germany and the Buck Institute for Research on Aging in California. It was an intervention-based assessment of immune aging, involving 50 middle-aged adults who received a four-week regimen of either Mitopure or a placebo.
The trial’s primary objectives were twofold: to increase the number of youthful, naive CD8 T-cells, which play a crucial role in fighting infections and age-related diseases, and to improve the mitochondrial activity of these cells, which tends to decline with age. Remarkably, both of these primary endpoints were successfully met in the Mitopure group compared to the placebo group.
New Breakthroughs
“This is groundbreaking research that helps us better understand how we can counter the age-related decline of our immune system,” said Dr. Eric Verdin, CEO and President of the Buck Institute, hailing the study’s findings. “It shows us that we can rewire our body’s defense with targeted mitochondrial interventions like Mitopure.”
Dr. Dominic Denk, the Principal Investigator of the MitoImmune Study, echoed these sentiments, suggesting that the findings could have important implications for the oncology community.
Timeline’s Next Steps
Encouraged by these promising results, Timeline is now expanding its research efforts through collaborations with other esteemed institutions. In partnership with the National Institute of Aging, the company is launching a new clinical trial to investigate the impact of Mitopure on glucose metabolism in middle-aged overweight adults, potentially shedding light on its ability to improve metabolic health and mitigate age-related metabolic decline.
“Our mission has always been to pioneer research that unlocks clinically proven interventions to help people stay healthier for longer,” said Chris Rinsch, PhD, Co-Founder and President of Timeline. “These results open a totally new approach to directly impact our immune cells and help restore their functionality during aging.”
A Bright Future
Building on 15 years of research and multiple clinical studies, Timeline appears poised to make significant strides in the realm of longevity research, offering hope for interventions that could potentially extend human healthspan.
Timeline is giving AGEIST readers 10% off any plan with code “AGEIST” at checkout.
